Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours

Next Previous
Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMO 103 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Intestinal cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Salivary gland cancer; Sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms MYCure
  • Sponsors Peptomyc

Most Recent Events

  • 04 Jun 2024 Pharmacokinetics results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 23 Apr 2024 The protocol has been amended to change in assessment of study primary outcome that is now only the Safety and Tolerability will be evaluated.
  • 23 Apr 2024 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top